Ed Hilt

Statistics

Publications

Citations

132

H-Index

Active since

2018

Affiliations

Bristol-Myers Squibb (United States)(Current)

University of Toronto

Princess Margaret Cancer Centre

Columbia University Irving Medical Center

Ed Hilt is an author at Bristol-Myers Squibb (United States) specializing in immune checkpoint inhibitors, checkpoint inhibitor therapy, and immunotherapy.

Publications per year

2018–2020

Publications

Abstract CT180: Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors

Lillian L. Siu, Howard A. Burris, Dung T. Le et al. · Cancer Research · 2018 · 64 citations

Pharmacy, Oncology, Pharmacology +17

An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors

Rui Wang, Chan Gao, Megan Raymond et al. · Clinical Cancer Research · 2019 · 43 citations

Medicine, Oncology, Pharmacology +17

Best practices for optimization and validation of flow cytometry‐based receptor occupancy assays

Ed Hilt, Yongliang Sun, Thomas W. McCloskey et al. · Cytometry Part B Clinical Cytometry · 2020 · 13 citations · Full text

Medicine, Cell Biology, Pharmacology +14

Abstract LB-127: From bench to bedside: Exploring OX40 receptor modulation in a phase 1/2a study of the OX40 costimulatory agonist BMS-986178 ± nivolumab (NIVO) or ipilimumab (IPI) in patients with advanced solid tumors

Rui Wang, Feng Yan, Ed Hilt et al. · Cancer Research · 2018 · 12 citations

Life Sciences, Immunology, Oncology +17

1–4 of 4